Dana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2020

  1. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 618-627